ODI Pharma AB (“ODI” or the “Company”) today announces a reverse profit warning following a significantly strong revenue development for the period October–December 2025 (Q2).   Preliminary and unaudited figures indicate that ODI achieved revenues of approximately SEK 11 million during the second quarter 2025/2026. This corresponds to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial increase compared to the corresponding quarter of the prev

Idag den 5 december 2025 hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.   Fastställande av resultaträkning och balansräkning Årsstämman beslutade att fastställa den framlagda resultaträkningen och balansräkningen samt koncernresultaträkningen och koncernbalansräkningen. Dispositioner beträffande bolagets resultat enligt den fastställda balansräkningen Årsstämman beslutade at

Today, the 5 th  of December 2025, ODI Pharma AB (publ) held its Annual General Meeting ("AGM"). Below is a summary of the decisions made. All decisions were made with the required majority.   Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to dispose of the compa

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website ( www.odipharma.com ). Below is a summary of the report.   First quarter (2025-07-01 – 2025-09-30) ·        The Group's net sales amounted to SEK 5,968,143 (143,793). ·        The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). ·       

ODI Pharma AB (“ODI Pharma” or the “Company”) provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market.   ODI Pharma’s commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Co